Destiny Pharma appoints Professor Mark Wilcox to Scientific Advisory Board
Search jobs Destiny Pharma appoints Professor Mark Wilcox to Scientific Advisory Board Destiny Pharma Plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, today announces the appointment of Professor Mark Wilcox to its Scientific Advisory Board (SAB). Professor Wilcox is a consultant microbiologist and Head of R&D in Microbiology at the Leeds Teaching Hospitals and is Lead on Clostridium difficile infection for Public Health England (PHE). He also has advisory rol...
Source: pharmiweb.com